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We  detected  two  types  of lymphocyte-mediated  cytotoxicity following antigenic 
stimulation  in vitro of lymphocytes from volunteers who had recently received a  live 
or inactivated influenza vaccine. In addition to detecting an increase in the influenza 
virus-specific HLA-restricted cytotoxic T  cell response, we observed a  lesser degree of 
cytotoxicity of target cells that was neither virus specific nor HLA restricted. 1 It was 
known that influenza infection in vivo (1, 2) and in vitro induced interferon  (3, 4), so 
we speculated that the nonspecific cytotoxicity was due to augmented  natural  killer 
cell activity of the cultured lymphocytes by interferon production in the culture. 
The  titers  of interferon  in  the  supernatant  fluids  of the  cultures  were  >10,000 
U/ml.  This  led  us  to  measure  the  production  of  interferon  by  influenza  virus 
stimulation of the lymphocytes of individuals who had not been vaccinated recently. 
In  addition  we  analyzed  the  kinetics  of interferon  induction,  the  nature  of the 
influenza antigen required, and the type of interferon produced. 
Materials  and Methods 
Virus Preparations.  Virus strains were grown in the allantoic sac of embryonated hens' eggs 
and were kindly provided by Dr. G. C. Sehild, National Institute for Biological Standards and 
Control (NIBSC), London, England. The strains used were A/PR/8/34 (HON1), A/Munich/ 
1/79 (H1N1), A/Port Chalmers/1/73 (H3N2), B/Hong Kong/5/72, A/Chick Germany/N/49 
(H10N7), A/Turkey Wisconsin/I/66 (H9N2), A/Equine/Prague/56  (H7N7), and A/Equine 
2/Miami/63  (H3N8). Whole virus vaccine concentrates containing 330 #g, respectively, of A/ 
Port  Chalmers/1/73  or  B/Hong  Kong/5/72,  hemagglutinin  (HA)  and  a  surface  antigen 
vaccine that contained 194 #g of A/England/321/77 (H3N2) hemagglutinin were provided by 
Dr. John Wood, NIBSC. Purified HA, obtained by disruption with Triton X-100 followed by 
fractionation on 20-50%  (wt/vol)  sucrose gradients,  and prepared  as described  (5)  from A/ 
Singapore/57 (H2N2), A/England/I/72  (H3N2), MRC-11  (H3N2), and a recombinant with 
Equine 1 HA and USSR neuraminidase designated H EqlN1 (H7N1) virus strains, were kindly 
given to us by Dr. J. Oxford (NIBSC). 
Stimulation of Lymphocytes.  Approximately 50  ml  of peripheral  blood containing  50  U  of 
preservative-free  heparin  was  diluted  with  a  half volume of medium  (RPMI  1640,  Gibco 
Laboratories, Grand Island Biological Co., Grand Island, N.Y.)  and layered onto Ficoll-Paque 
(Pharmacia, Uppsala, Sweden). These preparations were centrifuged at  1,400 rpm for 30 rain, 
and the layered buffy coats were removed and washed with the same medium three times.  The 
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cells were then counted and resuspended in the same medium containing 10% fetal calf serum. 
Some  of  these  lymphocytes  were  used  in  experiments  that  analyzed  the  HLA-restricted 
influenza-specific cytotoxic T cell response to vaccination.  1  The lymphocytes used in the present 
studies were resuspended into a concentration of 1.0 ×  106 cells/ml of medium with  10% fetal 
calf serum. 10% of the cells were exposed to 1 ml of either live virus (~ 1,000 hemagglutinating 
units of allantoic fluid-prepared virus), inactivated vaccine, or preparations of purified HA 
diluted with phosphate-buffered saline (pH 7.2) to contain 30 #g of HA/1.0 ml added to the 
stimulator cells, undiluted allantoic fluid, or medium alone. The aliquots of 10% of the cells 
were incubated with these various preparations for 90 min at 37°C in 5% CO2. These stimulator 
cells were then washed twice in medium with 10% fetal calf serum, and added to the remaining 
90% of the cells (responders). The mixed cells were cultured at 37°C in 5% CO2 for up to 7 d. 
The details of these methods have been described earlier, using both murine lymphocytes (6-8) 
and human lymphocytes (9,  10) exposed to influenza virus as stimulators of influenza-specific 
cytotoxic T  cell activity. 
Interferon Assay.  Interferon was assayed by a cytopathic effect reduction assay (11). Threefold 
serial dilutions of interferon samples were incubated with Hep2C cells for 20 h  at 37°C  and 
then challenged with encephalomyocarditis virus. An internal interferon standard was included 
in each set of assays, and titers read after a  further 48 h at 37°C. The international reference 
preparation of human leukocyte alpha interferon (69/19)  reproducibly titered at 3,000  U/ml 
in this assay; i.e.,  1 laboratory unit was equivalent to  1.67 IU/ml with respect to the 69/19 
human  leukocyte interferon standard in the absence of a  recognized international reference 
preparation for human gamma interferon. 
Neutralization  of Interferon.  Neutralization  of antiviral  activity was  carried  out  by  using 
specific antisera to human alpha and beta interferons. Calf and sheep antihuman  interferon 
[a(Ly)] antisera were obtained by immunizing animals with partially purified human lympho- 
blastoid interferon [HuIFNa(Ly)] obtained from Wellcome Research, Beckenham, Kent, Eng. 
Rabbit  antihuman  FS4  fibroblast beta  interferon  was  a  gift  from  Dr. J.  Vilcek,  Dept.  of 
Microbiology, New York University School of Medicine, New York. Diluted interferon samples 
containing  10  U/ml  were  incubated  for  2  h  at  room  temperature with  serial dilutions of 
antiserum, and then the residual interferon was titrated in the CPER assay. The neutralizing 
titer of the antiserum is expressed as the dilution of antiserum required to totally ablate the 
antiviral activity of an interferon preparation containing 10 U/ml. 
Results 
The interferon titers summarized in Table I were obtained on supernatant fluids of 
lymphocyte cultures,  prepared  from  the  lymphocytes of volunteers  who  had  been 
given  influenza  vaccine  14  and  180  d  earlier.  There  were  36  individuals who  had 
received either a  live attenuated vaccine, or one of two types of inactivated vaccine, 
whole virus, or surface antigen. Results indicate that the lymphocytes of the volunteers, 
after in vitro exposure to stimulator lymphocytes treated with live virus (A/Munich/ 
1/79  [H1N1],  antigenically similar to  the  virus  strains  in  the  vaccines),  produced 
interferon,  and  lymphocytes  not  exposed  to  the  stimulator  lymphocytes  did  not. 
Lymphocytes from individuals given any of the three vaccines produced high amounts 
of interferon after exposure to stimulator lymphocytes when  the culture fluids were 
tested  7  d  later.  The  mean  interferon  responses  were  above  10,000  U/ml  for each 
vaccine  group  at  14  d  after  vaccination.  This  decreased  somewhat  by  180  d  after 
vaccination, when  the mean  responses of the volunteers lymphocytes were  ~/4,000 
U/ml  for the three vaccine groups. 
We next examined the production of interferon by influenza virus stimulation of 
lymphocytes of normal adult blood donors, who had not received influenza vaccine. 
Table II summarizes the titers of interferon measured  in these lymphocyte cultures. 
It is clear that cultured lymphocytes exposed to virus-treated stimulator cells produced FRANCIS  A.  ENNIS  AND  ANTHONY  MEAGER  1281 
TABLE  I 
Interferon Production* by the Lymphocytes of Vaccinated Volunteers following In  Vitro Stimulation with 
A/Munich/ l/79 (HIN1)  Virus 
Live vaccine  Intact whole virus  Surface antigen 
Volun-  14  180~  Volun-  14  180  Volun-  14  180 
teer  teer  teer 
12  4.3  2.7  13  3.8  2.6  14  4.5  3.4 
15  4.0  2.6  16  4.3  2.7  17  4.0  2,2 
21  4.0  3.2  19  4.0  3.4  20  4.0  3.0 
24  4.5  2.9  22  4.0  3.3  23  4.5  2,4 
27  4.5  2.2  25  4.0  --  26  4.5  3.4 
30  4.5  4.1  28  4.0  3.3  29  2.5  2.8 
33  4.0  2.9  34  4.5  3.7  32  3.5  2.4 
36  4.0  --  37  3.5  2.5  35  4.5  1.2 
39  4.5  --  43  4.5  3.2  38  4.5  3.6 
42  4.5  4.2  46  4.0  3.3  41  4.5  -- 
45  4.0  2.8  49  4.0  4.7  50  4.5  4.4 
51  4.5  2.8  52  4.0  1.4  54  4.0 
Mean  4.34  3.5  4.13  3.78  4.34  3.6 
* Interferon values are expressed as loglo IU/ml. 
:~ 14  and  180  designate the interferon produced by lymphocyte cultures established 14 and  180  d  after 
vaccine was administered. 
TABLE  II 
Interferon Production* by Lymphocytes of Platelet Donors by In Vitro Stimulation 
with Influenza Viruses 
Virus added to stimulator cells 
Donor  A/Munich/ 
None  A/PC/I/73  A/PR/8/34  1/79  B/Hong 
(H3N2)  (HON1)  (H1NI)  Kong/5/72 
56  0  1.7  1.4  --:~  1.7 
57  0  1.7  1.6  --  1.7 
58  0  3.0  2.7  --  2.7 
59  0  2.6  3.1  --  3.0 
60  0  3.2  3.2  --  3.2 
61  0  2.7  2.7  --  2.7 
62  0  3.4  3.5  --  3.8 
63  0  3.8  3.7  --  3.7 
64  0  2.7  2.5  2.0  2.7 
65  0  3.0  2.9  2.5  2.9 
66§  0  2.5  2.0  --  2.0 
67§  0  2.7  2.7  --  3.0 
70~  0  2.5  2.5  --  3.0 
75  0  2.2  --  --  2.7 
76  0  2.5  --  --  3.5 
61R  0  2.5  2.8  --  -- 
Mean  3.0  3.03  2.32  3.17 
* Interferon values are expressed as logl0 IU/ml. 
:~ --, not performed. 
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TABLE  III 
Interferon Production * by Human Lymphocytes  Stimulated by Human Influenza 
Viruses,  Vaccines, Purified HA, and by Nonhuman Influenza  Viruses 
Virus added to stimulator cells 
Donors 
62  63  68  69  75  76 
Human viruses 
A/PR/8/34 (HON1)  3.5  3.6  2.7  3.0  --  -- 
A/PC/1/73 (H3N2)  3.3  3.5  2.5  2.7  2.2  2.5 
B/Hong Kong/5/72  3.5  3.5  3.7  2.7  2.7  3.5 
Nonhuman viruses 
A/Eq/1/56  3.0  3.2  .... 
A/Eq/2/63  3.0  3.2  2.7  2.4  --  -- 
A/Turkey/N/66  3.2  3.4  2.5  2.7  --  -- 
A/Chick/N/49  3.2  3.6  2.9  2.7  --  -- 
Inactivated vaccine 
A/Port Chalmers/l/73  ....  1.0  1.7 
B/Hong Kong/5/72  ....  1.5  2.0 
A/England/1/72  ....  0  0 
surface antigen vaccine 
Purified  HA 
A/Sing/57 (H2)  0  0  .... 
A/Eng/1/72 (H3)  --  --  0  0  --  -- 
MRC-l I (H3)  --  --  0  0  0  0 
H/EqlN1 (Eql)  --  --  0  0  --  -- 
Allantoic fluid  --  --  0  0  --  -- 
Controls  0  0  0  0  0  0 
* Interferon  values  are  expressed  in  log10 IU/ml  and  were  measured  7  d  after 
stimulation. 
interferon, and  that  such stimulation  was necessary  for production.  Several influenza 
virus strains  were used  to  infect  stimulator  lymphocytes,  and  all  induced  interferon. 
The  lymphocytes  of some  donors  produced  higher  levels of interferon  to  all  of the 
virus strains, whereas others produced somewhat  lower levels. The level of production 
of interferon  was  similar  for any  one lymphocyte  donor  after stimulation  by  any  of 
the virus strains.  Repeat  testing of the  lymphocytes  from one donor  3  mo later gave 
similar interferon titers  (61  and  61R). 
The results  in Table  II indicated  that  stimulator  cells exposed  to several influenza 
A  viruses of the H0N 1, H  1N 1, and  H3N2  subtypes,  as well as influenza B, stimulated 
interferon  production.  The  results  of exposure  of responder  lymphocytes  in  vitro  to 
stimulator lymphocytes treated with live infectious human  virus, inactivated whole or 
surface  antigen  vaccine,  purified  HA  preparations,  and  live nonhuman  viruses,  are 
contained  in Table  III.  Lymphocytes cultured  without  virus-treated  stimulator  cells, 
following treatment  with  allantoic  fluid-treated  stimulator  cells,  or  following treat- 
ment  with  medium-treated  stimulator  cells, did not  produce  interferon.  All lympho- 
cyte  cultures  with  live,  human  or  nonhuman,  virus-treated  stimulator  lymphocytes 
produced  interferon.  Two  inactivated whole virus  vaccines induced  some,  but  lower, 
levels  of  interferon,  and  no  interferon  was  detected  in  the  cultures  containing 
stimulator  cells  treated  with  an  inactivated  surface  antigen  vaccine.  No  interferon 
was produced  when stimulator  lymphocytes were exposed to preparations  of purified 
HA  prepared  from  an  H2N2,  H3N2,  or HeqlN1  virus strain.  These  results  indicate FRANCIS A. ENNIS AND ANTHONY  MEAGER  1283 
TABLE IV 
Time-Course of Interferon* Production by Lymphocytes  Stimulated by Influenza 
Virus added to  Donor  Time after stimulation  stimulator cells 
Day 1  Day 4  Day 7 
64  A/Port Chalmers (H3N2)  2.7  2.7  2.7 
A/Munich (H1N1)  2.2  2.2  1.95 
A/PR/8 (HON  1)  2.7  2.7  2.45 
B/HK/5/72  2.95  2.9  2.65 
66 
Day 1  Day 5 
A/Port Chalmers (H3N2)  1.7  2.45 
A/PR/8 (HON1)  1.2  1.95 
B/HK/5/72  1.2  1.95 
1.5h  4h  24h  72h 
70  A/Port Chalmers (H3N2)  0  0  1.9 (1.4):~  2.5 (0)§ 
A/PR/8 (HONI)  0  0  1.9 (1.4)  2.5 (0) 
B/HK/5/72  0  0  2.1 (1.65)  3.0 (0) 
* Interferon values are expressed as log10 IU/ml. 
:~ Units of interferon measured after 24 h in culture with a change in medium at 4 h are indicated in 
parentheses. 
§ Units of interferon measured after 72 h in culture with a change in medium at 4 h and 24 h are indicated 
in parentheses. 
TABLE V 
Characteristics of lnterferons Produced by Influenza-stimulated Lymphocyte Cultures 
Interferon  Percent 
Donor  Stimulator viruses  Untreated  level  pH 2  pH 2 la- 
treatment*  bile 
26  A/Munich/1/79 (HINI)  4.2  3.2  90 
63  A/PR/8 (HONI)  3.2  2.5  80 
A/Eq 1/56 (HeqlNeql)  2.9  2.5  60 
A/Chlck/N/49  3.5  2.7  84 
A/Turkey/N/46  3.1  2.5  75 
* Interferon values are expressed as loglo  IU/ml. 
that the stimulator cells must be exposed to intact virus in order for interferon to be 
stimulated in the cultures. Inactivated vaccines that contained intact virus particles 
also induced interferon, but to a  lesser degree; surface antigen vaccine and purified 
HA preparations did not. It was interesting to observe that several nonhuman viruses 
also induced interferon to titers similar to those produced by the human viruses. 
The production of interferon occurred within the first few days of culture and was 
stable or fell slightly by day 7, as shown in Table IV. Changing the medium after 4 
h  of culture reduced the yield, and changing medium at 4  and 24 h  resulted in the 
absence of interferon in the cultures when tested at 72 h  (Table IV). 
The results shown in Tables III and IV suggested that interferon induction resulted 
from exposure of responder lymphocytes to stimulator cells treated with intact viruses. 
These stimulator cells induced interferon in the culture, but production of interferon 1284  INFLUENZA  STIMULATION OF GAMMA INTERFERON 
TABLE VI 
Effect of Treatment of lnfluenza-stimulated Lymphocyte Culture Fluids with 
Antiserum to Human Lymphoblastoid Interferon 
Donor  Virus stimulator 
Antibody level* 
Untreated  pH 2 treatment 
63  A/PR/8 (HON1)  3,000  1,000,000 
A/Eq/1/56 (HeqlNeql)  100,000  1,000,000 
A/Chick/N/49  10,000  300,000 
16  A/Munich/1/79 (H1N1)  <100  300,000 
26:~  A/Munich/I/79 (H1N1)  <100  300,000 
* Dilution of sheep antiinterferon [a(Ly)] which has a neutralizing titer of 300,000- 
1,000,000 against 10 IU human lymphoblastoid interferon, at which it neutralized 
10 U of antiviral activity in the supernatant  fluid. This antiserum was used in all 
assays except in  the  ease of donor  16, when a similar calf antiserum  to a(Ly) 
interferon was used. 
:~ In this case interferon was passed through an NK2 monoclonal antibody to alpha 
interferon column (Secher and Burke, 13). The untreated sample is representative 
of the  flow-through or unbound  fraction, and  the  pH  2-treated sample is  that 
fraction eluted with pH 2 buffer from the immunoabsorbent column. 
appeared to be mediated by a  factor released into the medium, the removal of which 
was associated with a  decrease in interferon production. 
Studies  were  performed  to  analyze  the  type  of interferon  induced.  The  results 
presented in Table V  indicate that most of the interferon produced was labile at pH 
2. Supernatant  fluid from a culture of lymphocytes established  14 d after vaccination 
had a 90% drop in interferon titer after pH 2 treatment.  Decreases were also produced 
in  the  interferon  level  after  pH  2  treatment  of the  culture  fluids  of lymphocytes 
exposed  to  virus-treated  stimulator  cells  of the  donors  not  vaccinated  (donor  63). 
These observations suggested that gamma (immune) interferon, which is known to be 
acid labile,  was being produced  in  the  lymphocyte cultures  after exposure  to virus- 
treated  stimulator  cells  having  influenza  antigens  on  their  membranes.  Although 
some of the interferon remained after pH 2 treatment and may have been induced by 
virus infection rather  than  immune recognition,  no infectious  virus was detected  in 
the interferon containing supernatant  fluids when they were tested on Madin-Darby 
canine kidney cells, which are very sensitive  for detecting  live influenza  viruses  (12) 
(data not shown). 
Treatment  of several of the interferon-containing supernatant  fluids with antisera 
to alpha interferons neutralized  the pH 2 stable interferon  (Table  IV). The antisera 
did  not  decrease  the  activity  of the  interferon  detected  in  untreated  supernates  of 
lymphocyte cultures  obtained  from recently  vaccinated  individuals  (donors  16  and 
26), but had some activity against  the interferon produced in cultures of individuals 
who were not vaccinated. Antiserum to beta interferon had no effect on the interferon 
produced by lymphocyte cultures of either vaccinated or unvaccinated donors (data 
not shown). The data shown in Tables V  and VI suggested that lymphocyte cultures 
exposed  to influenza  virus-treated  stimulator  cells  contained  mixtures  of alpha  and 
gamma interferons,  with  a  larger component of gamma interferon,  especially in the 
cultures of lymphocytes from the recently vaccinated volunteers. 
In an attempt to further characterize the mixture of interferons, the supernate from 
donor  26  was  passed  through  an  NK2  monoclonal  antibody  to  alpha  interferon- FRANCIS  A.  ENNIS  AND  ANTHONY  MEAGER  1285 
Sepharose 4B immunoabsorbent column (13).  Only 5% of the interferon was bound 
to the column and  this was eluted with a  pH  2 buffer. The flow-through solution 
contained  >90%  of the  interferon  activity  added  to  the  column.  This  interferon 
remained  pH  2  labile  and  was  not  neutralized  by  antiserum  to  alpha  interferon 
(Table VI). 
Partial purification of interferon in the pooled supernate of lymphocyte cultures 
from  recently  vaccinated  volunteers  by  control  pore  glass  and  concanavalin  A- 
Sepharose 4B chromatography (14) revealed two components. The first did not bind 
to concanavalin  A-Sepharose,  and  the  second was  eluted with  0.1  M  a-methyl-D- 
mannoside. This second component, comprising ~50% of the input interferon activity, 
had elution characteristics identical to gamma interferon from phytohemagglutinin- 
stimulated human lymphocytes purified in the same way. 
Discussion 
Our  results  indicated  that  high  levels of immune  interferon were  produced  by 
exposure of human lymphocytes in culture to stimulator ceils that had been treated 
with  influenza  virus..The  lymphocytes of individuals  who  had  recently received 
influenza vaccine produced the  highest  levels of interferon, and  their lymphocytes 
still produced high levels when tested 6 mo after vaccination. At 6  mo the level of 
interferon produced was  still considerably higher than that  detected in cultures of 
lymphocytes obtained  from donors who had  not  received the  vaccine. These data 
suggest that human lymphocytes with memory for influenza virus antigen(s) expand 
following exposure in vivo by vaccination. When subsequently exposed to influenza- 
treated stimulator ceils in vitro, these memory cells further expand and produce large 
amounts of immune interferon. In the absence of recent antigenic stimulation in vivo, 
human lymphocyte cultures produce immune interferon following exposure to influ- 
enza virus-treated stimulator cells, but at a  lower level. The interferons produced in 
the  cultures  were  a  mixture,  but  a  high  concentration of immune  interferon was 
produced, especially in the cultures of lymphocytes from recently vaccinated individ- 
uals. 
The  responding  lymphocytes  apparently  recognized  influenza  antigens  on  the 
stimulator cells. The nature of the antigen recognized has not been defined. It must, 
however, be shared by human and nonhuman influenza A viruses, because stimulator 
cells treated with either resulted in interferon production by the lymphocytes. The 
antigen was most efficient at inducing interferon when a live virus was used. Induction 
of interferon appeared to require exposure of stimulator cells to an intact virus, as 
purified HA and  a  surface antigen  vaccine preparation  containing HA and  neur- 
aminidase  did  not  induce  interferon.  The  need  for intact  virus  suggests  that  the 
structure  containing  the  stimulating  antigen  is  important  for proper presentation 
and/or processing of antigen to occur. These results indicated that isolated HA was 
not  satisfactory for treating  the  stimulator  cells  for inducement  of interferon, but 
nevertheless, the HA on the surface of the intact  virus may be the antigen that  is 
recognized. If HA antigen is responsible for inducing immune interferon production 
it must  be by a  cross-reactive determinant of the HA present on both human  and 
nonhuman  influenza viruses.  It  is  also possible that  a  shared determinant of some 
other antigen, neuraminidase, nucleoprotein, or matrix was recognized by the respond- 
ing lymphocytes and  resulted in  the production of interferon. Recent studies  have 1286  INFLUENZA STIMULATION OF GAMMA INTERFERON 
indicated that monoclonal antibodies to HA and neuraminidase bind to the murine 
myeloma cells P815  when they are infected with influenza viruses, and to a  lesser 
degree antibody to nucleoprotein. Antibody to matrix did not bind (15). These types 
of experiments performed on human lymphoeytes following infection with influenza 
virus  might  help  define  the  nature  of the  antigen  recognized  by  the  responding 
memory lymphocytes. 
The levels of gamma interferon produced in these experiments were much higher 
than has been previously reported. Addition of influenza virus directly to cultured 
human peripheral blood lymphocytes, without pretreating stimulator cells, resulted 
in the production of a few hundred units of pH 2-stable interferon, neutralized by an 
antiserum to alpha interferon, and appearing to be mainly produced by nonadherent 
cells (16). Other reports have also described the production of moderate amounts of 
classical virus-induced alpha interferon stable at pH 2 following virus stimulation of 
cultured lymphocytes (17-20). The results of the experiments reported herein contrast 
with previously published reports because much higher levels of pH 2-labile gamma 
interferon were detected following exposure of human lymphocytes to virus-treated 
stimulator cells  in  the  present  studies.  We  used  this  method  for presenting  virus 
antigen to memory T  cells because it is a  very effective way to stimulate the H2- or 
HLA-restrieted influenza virus-specific cytolitic T  lymphocytes (CTL) response. This 
technique was used for measuring HLA-restricted CTL responses in the volunteers 
who had received the vaccines. This method has not been previously reported to result 
in  high  levels  of  gamma  interferon  production.  Apparently,  the  recognition  of 
influenza antigen on the stimulator cells by the responding lymphocytes resulted in 
increased immune interferon production as well as in stimulating the HLA-restricted 
virus-specific cytotoxic T  cell response, x There may be an interrelationship between 
the  induction  of gamma  interferon  and  the  cytotoxic T  cell  response  involving 
interleukin  2,  as  suggested  by  Farrer  et  al.  (21) who  reported  that  interleukin  2 
appeared necessary for production of gamma interferon, and cytotoxic T cell responses 
in mixed leukocyte cultures. 
Other  methods of producing gamma interferon have generally used  nonspecific 
mitogens, rather than antigens, as inducers. In general, the levels of gamma interferon 
that  have  been  induced  by  stimulation  with  mitogens  such  as  eoncanavalin  A, 
phytohemagglutinin,  and  staphylococcal  enterotoxin  A  have  been  -100-800  U 
interferon/10  s  cells  (22,  23).  Mixed  lymphocyte cultures  have  been  reported  to 
produce -10 U/106 cells (24). These levels are much lower than the titers of immune 
interferon produced in the present studies, i.e., up to 50,000  U/106 cells from most of 
the recently vaccinated individuals, and ,,-4,000  U/10 s cells 6 mo after vaccination. 
The lymphocyte cultures of normal adult blood donors produced ~ 1,000 U/l0  s cells. 
The  explanation  for  the  observation  of such  high  levels  of immune  interferon 
production is not clear. It is possible that humans, as a  result of repeated infection 
with influenza viruses, have been stimulated numerous times with the cross-reactive 
antigen recognized by memory T  cells, resulting in these levels of immune interferon 
production. The further increase in immune interferon production obtained by using 
the lymphocytes of recently vaccinated individuals would support this hypothesis. It 
may also be speculated that the cross-reactive determinant recognized by and resulting 
in immune interferon production is the same determinant recognized by one popu- 
lation  of cytotoxic  T  lymphocytes.  This  population,  unlike  the  subtype-specific FRANCIS A.  ENNIS AND ANTHONY MEAGER  1287 
cytotoxic antibody (25) and cytotoxic T cells (26, 27), kills target cells across influenza 
virus subtypes (28-30). 
The ability to stimulate lymphocytes in vitro following recent in vivo stimulation 
is a method of antigenic stimulation of immune interferon that may be applicable to 
many antigens. The in vitro infection of stimulator cells appears, however, to produce 
the best yields of immune interferon as a response to influenza antigens. The levels of 
immune interferon produced by this method far exceed the levels of both alpha and 
gamma interferon previously reported following infection of lymphocyte cultures by 
viruses, including influenza (16-18), and by mitogens (21-23). 
Summary 
Influenza virus stimulation of human lymphocytes induced high levels of immune 
interferon  in  lymphocyte  cultures.  The  lymphocytes  of  normal  adults  produced 
-1,000 U/106 cells, which was in large part gamma interferon. The lymphocytes of 
individuals  recently  vaccinated  yielded  very high  levels  (10-50,000  U/106  cells)  of 
interferon.  The interferon  was pH  2  labile,  and was not  neutralized  by antisera to 
alpha or beta interferon. It did not bind to a monoclonal antibody to alpha interferon, 
and  after  partial  purification  it  had  characteristics  identical  to  human  gamma 
interferon  induced  by  phytohemagglutinin.  The  highest  yields  were  produced  by 
treatment of stimulator cells with live virus. Stimulation  by whole inactivated virus 
resulted  in  lower  levels  of interferon,  and  purified  hemagglutinin  did  not  induce 
interferon.  The  antigen  responsible  for  stimulating  the  lymphocyte  response  and 
interferon induction  is a  cross-reactive determinant  present on all human and non- 
human influenza viruses tested. 
Received  for publication 8July  1981. 
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